Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025
Accumulated OCI remains negative
Q4 FY2025 Accumulated OCI was $0, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Accumulated OCI amounts to 0.0% of total assets for NNNN, versus a peer median of 2.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$42.89M CAD | -9.1% | +6.8% | 3.3% | |
| Mar 2026 | $5.54M USD | — | — | 5.9% | |
| Feb 2026 | $2.71M USD | +176.6% | — | 1.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | — | — | 0.0% |
| Mar 2026 | -$43K USD | -259.3% | — | 0.0% | |
| Mar 2026 | -$128K USD | -6300.0% | — | 0.0% | |
| Mar 2026 | -$4.02M USD | -388.3% | — | 3.1% | |
| Dec 2025 | -$7.13M USD | — | — | 2.1% | |
| Mar 2026 | -$10M USD | -42.9% | — | 0.1% | |
| Mar 2026 | -$14.8M USD | +9.3% | — | 2.8% | |
| Mar 2026 | -$36M USD | +14.9% | — | 3.4% | |
| Peer median (excluding NNNN) | — | -26.0% | +6.8% | 2.5% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.